Physician profile
James Henry Flores, JR.
NPI 1720166481
$4,278.27
in general payments reported to CMS, 2019-2025
24 companies · $700 in 2025
The $700 reported for 2025 was more than what 95% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $562 · 2021: $648 · 2022: $604 · 2023: $565 · 2024: $349 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564 · Honoraria: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.56 |
| Honoraria | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $886.61 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $725.57 | 2019-2023 | Bexsero |
| Merck Sharp & Dohme LLC | $656.13 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $339.27 | 2019-2020 | |
| Sanofi Pasteur INC. | $336.42 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $250.57 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $215.44 | 2021-2024 | Qelbree |
| Kaleo, INC. | $188.68 | 2019-2023 | Auvi-Q |
| Cranial Technologies, INC | $111.38 | 2019-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $96.33 | 2020-2022 | |
| Sobi, INC | $86.47 | 2019 | |
| Mckesson Medical-Surgical, INC. | $65.00 | 2021-2023 | |
| Alk-Abello, INC | $43.88 | 2023-2025 | Neffy, Grastek, Ragwitek |
| Tris Pharma INC | $42.51 | 2020-2022 | |
| Abbott Laboratories | $41.52 | 2025 | Id Now Instrument |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $37.86 | 2019 | |
| Seqirus USA INC | $26.40 | 2025 | Flucelvax |
| Noven Therapeutics, LLC | $20.43 | 2024 | Xelstrym |
| Arbor Pharmaceuticals, INC. | $19.18 | 2020 | |
| Phadia US INC. | $18.47 | 2022 | |
| Adlon Therapeutics L.P. | $18.45 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $17.87 | 2023 | Neo-Synalar |
| Neos Therapeutics, Lp | $17.35 | 2019 | |
| Organon LLC | $16.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.